emka TECHNOLOGIES - Events calendar and news

upcoming events

Safety Pharmacology Society 2008 8th Annual Meeting

SPS 2008 - September 23-24, 2008 - Madison, Wisconsin - booth# 706 - come visit us!
www.safetypharmacology.org

Make sure you dont miss our side meeting on September 23rd!

Carlos Del Rio, PhD, of Qtest Labs, will present a set of studies he conducted to formally compare the signal characteristics of single-lead electrocardiograms simultaneously collected in beagle dogs using non-invasive and invasive telemetry techniques, and a hard-wire setup. In particular, the properties, response, and performance of a wearable (non-invasive) telemetry system (emkaPACK; emka TECHNOLOGIES) will be evaluated side-by-side against a standard implantable system.

These comparisons will be performed using a common data acquisition/analysis system under a variety of physiological conditions commonly encountered/required in cardiovascular research and/or pre-clinical testing (pharmacological challenge, exercise test, anesthesia, etc.).

In addition, the performance and response characteristics of minimally invasive, vascular access port-derived telemetered pressure signals will be evaluated.

---

SURVEY OF INDUSTRY: IDENTIFYING CONSORTIA PROJECTS ADDRESSING SIGNIFICANT PUBLIC HEALTH CONCERNS

Ganderup, N.C1, Burton, J2.

1: Ellegaard Göttingen Minipigs, Dalmose, Denmark

2: EMKA Technologies, Falls Church, VA, USA

Abstract

Consortia collaborations offer a fast and efficient way to develop methods and scientific understanding in principal areas of research. This survey, conducted with the support of the Safety Pharmacology Society, had several objectives: to identify ongoing consortia projects probing areas in the field of safety pharmacology, and to make available to the SPS’s members, information about these programs. Lessons learned, in terms of managing and contributing in such projects will be presented. The potential role of the SPS as a facilitator of such projects will also be explored. This will hopefully kick off a discussion about the value of collaborative programs and their potential benefits to the participants.

A survey was e-mailed to members of the SPS. Responses were collected online. 14 projects involving more than 30 companies were identified. The projects covered the areas of drug-induced pro-arrhythmia (5), drug-induced cardiotoxicity (3), drug dependence and abuse liability (2), zebra fish as a pre-clinical model (2), study of human ion channels (1), and comparative biology and scaling of results across different species (1).

The SPS is in a unique position to take the lead by collecting and disseminating information about consortia projects (both completed and in-progress) and identifying new areas where further research is needed. Creation of Special Working Groups around specific topics under the auspices of the SPS could serve to facilitate consortia projects to the benefit of patients, safety pharmacologists, the society, and regulatory bodies alike.

> return to previous page